| Mechanism | Indication | Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 | Ownership | PIPE-791 |
|---|---|---|---|---|---|---|---|---|
| LPA1R Antagonist | IPF* | Wholly-owned | ||||||
| close x | ||||||||
| LPA1R Antagonist | PPMS/SPMS* | Wholly-owned | ||||||
| close x | ||||||||
| LPA1R Antagonist | Pain** | Wholly-owned | ||||||
| close x | CTX-343 | |||||||
| LPA1R Antagonist | Peripheral | Wholly-owned | ||||||
| close x | PIPE-307 | |||||||
| M1R Antagonist | RRMS | In Collaboration with Johnson & Johnson | ||||||
| close x | ||||||||
| M1R Antagonist | Depression | In Collaboration with Johnson & Johnson | ||||||
| close x | ||||||||
| LPA1R Antagonist
IPF* | ||||
| Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|
Wholly-owned | ||||
| LPA1R Antagonist
PPMS/SPMS* | ||||
| Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 |
Wholly-owned | ||||
| LPA1R Antagonist
Pain** | ||||
| Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 |
Wholly-owned | ||||
| LPA1R Antagonist
Peripheral | ||||
| Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 |
Wholly-owned | ||||
| M1R Antagonist
RRMS | ||||
| Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 |
In Collaboration with Johnson & Johnson | ||||
| M1R Antagonist
Depression | ||||
| Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 |
In Collaboration with Johnson & Johnson | ||||
* Partnered
**Wholly-owned
LPA1R Antagonist
Our wholly-owned lead asset, PIPE-791, is a novel, brain penetrant, small molecule antagonist of the lysophosphatidic acid 1 receptor (LPA1R) in development for the potential treatment of idiopathic pulmonary fibrosis (IPF). We plan to commence a Phase 1b open-label trial in IPF to measure lung receptor occupancy by positron emission tomography (PET) imaging, which will inform dose selection for future clinical development in Phase 2a trials.
LPA1R Antagonist
Our wholly-owned lead asset, PIPE-791, is a novel, brain penetrant, small molecule antagonist of the lysophosphatidic acid 1 receptor (LPA1R) in development for the potential treatment of progressive multiple sclerosis (Progressive MS). We plan to commence a Phase 1b open-label trial in Progressive MS to measure brain receptor occupancy by positron emission tomography (PET) imaging, which will inform dose selection for future clinical development in Phase 2a trials.
LPA1R Antagonist
Our wholly-owned lead asset, PIPE-791, is a novel, brain penetrant, small molecule antagonist of the lysophosphatidic acid 1 receptor (LPA1R) in development for the potential treatment of chronic pain. We expect to launch an exploratory Phase 1b, randomized, double-blind, placebo-controlled, crossover, multi-center study in the first quarter of 2025.
LPA1R Antagonist
In January 2024, we nominated and began preclinical studies for CTX-343, a peripherally restricted (unable to cross the blood-brain-barrier) LPA1R antagonist. CTX-343 represents the third internally development candidate to be generated from our drug discovery platform. We expect to submit an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for CTX-343 in 2025.
M1R Antagonist
PIPE-307 is being developed pursuant to a global license and development agreement with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
M1R Antagonist
PIPE-307 is being developed pursuant to a global license and development agreement with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
* Single Phase 1 clinical trial of PIPE-791 for the potential treatment of IPF and Progressive MS.
**Exploratory Phase 1b, randomized, double-blind, placebo-controlled, crossover, multi-center study is expected to begin in the first quarter of 2025.
PIPE-791
PIPE-791 – IPF*
Our wholly-owned lead asset, PIPE-791, is a novel, brain penetrant, small molecule antagonist of the lysophosphatidic acid 1 receptor (LPA1R) in development for the potential treatment of idiopathic pulmonary fibrosis (IPF). We plan to commence a Phase 1b open-label trial in IPF to measure lung receptor occupancy by positron emission tomography (PET) imaging, which will inform dose selection for future clinical development in Phase 2a trials.
PIPE-791 – PPMS-SPMS*
Our wholly-owned lead asset, PIPE-791, is a novel, brain penetrant, small molecule antagonist of the lysophosphatidic acid 1 receptor (LPA1R) in development for the potential treatment of progressive multiple sclerosis (Progressive MS). We plan to commence a Phase 1b open-label trial in Progressive MS to measure brain receptor occupancy by positron emission tomography (PET) imaging, which will inform dose selection for future clinical development in Phase 2a trials.
PIPE-791 – Chronic Pain**
Our wholly-owned lead asset, PIPE-791, is a novel, brain penetrant, small molecule antagonist of the lysophosphatidic acid 1 receptor (LPA1R) in development for the potential treatment of chronic pain. We expect to launch an exploratory Phase 1b, randomized, double-blind, placebo-controlled, crossover, multi-center study in the first quarter of 2025.
CTX-343
In January 2024, we nominated and began preclinical studies for CTX-343, a peripherally restricted (unable to cross the blood-brain-barrier) LPA1R antagonist. CTX-343 represents the third internally development candidate to be generated from our drug discovery platform. We expect to submit an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for CTX-343 in 2025.
PIPE-307
PIPE-307 is a novel, small molecule, selective inhibitor of the muscarinic type 1 M1 receptor (M1R), in development for relapse-remitting multiple sclerosis (RRMS) and depression. We have completed two Phase 1 trials of PIPE-307 in healthy volunteers. We have initiated a Phase 2 trial of PIPE-307 for the potential treatment of RRMS. Contineum is developing PIPE-307 in collaboration with Johnson & Johnson Innovative Medicines (J&J).
